COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 5 FDA records to the applicant name Abbott Vascular (Idef Technologies Inc). It includes 1 original PMA approval. 2 entries are PMA supplements. 2 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Mar 28, 2014 to Nov 6, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code NIP appears in 5 of the 5 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P120020, with 5 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 3200 Lakeside Dr., Santa Clara, CA, 95054. Recorded on P120020/S037, decision dated Nov 6, 2026.
Device categories in this collection
Stent, Superficial Femoral Artery.
Changes described in PMA records
The FDA recorded an approval decision on 2026-11-06 for P120020/S037, a Special (Immediate Track) supplement to the Supera Peripheral Stent System premarket approval held by Abbott Vascular (Idef Technologies Inc). The supplement reason is listed as a labeling change covering indications, instructions, shelf life or tradename. The recorded scope is limited to revisions of the Instructions for Use and patient guide that modify warnings, precautions and contraindications, plus the magnetic resonance imaging labeling.
This action amends labeling for an already-approved stent system; it is not a new approval of the device itself. The source record does not state which warnings, precautions, contraindications or MRI labeling text changed, nor does it include the revised documents, so the substance of the revisions remains unknown. No clinical, efficacy or patient-selection conclusions follow from this entry.
The device category is recorded as a stent for the superficial femoral artery, with product code NIP and Cardiovascular specialty. The source data do not describe components, materials or delivery system details.
FDA approval-order wording
Approval for revisions to the Instructions for Use and patient guide to modify warnings, precautions and contraindications, and the magnetic resonance imaging labeling
Nov 6, 2026 · Special (Immediate Track)FDA’s recorded scope: approval of a modified sterilization cycle at chamber C, 7, and 8 at Sterigenics Los Angeles and chamber 2 and 3 at Sterigenics Costa Rica
Mar 20, 2026 · 30-Day NoticeFDA’s recorded scope: approval for a change to the outer sheath coating solution process
Feb 5, 2026 · 30-Day NoticeFDA’s recorded scope: approval for a manufacturing site located at Synergy Health AST, SRL, B13.1 Street 4, Avenue 1, Coyol Free Zone, Coyol, Alajuela, 20102, Costa Rica for sterilization.
Dec 9, 2025 · Normal 180 Day Track No User FeeFDA’s recorded scope: APPROVAL FOR THE SUPERA PERIPHERAL STENT SYSTEM. THIS DEVICE IS INDICATED TO IMPROVE LUMINAL DIAMETER IN THE TREATMENT OF PATIENTS WITH SYMPTOMATIC DE NOVO OR RESTENOTIC NATIVE LESIONS OR OCCLUSIONS OF THE SUPERFICIAL FEMORAL ARTERY (SFA) AND/OR PROXIMAL POPLITEAL ARTERY, WITH REFERENCE VESSEL DIAMETERS OF 4.0 TO 6.5 MM, AND LESION LENGTHS UP TO 140 MM.
Mar 28, 2014Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.